human
rhinovirus
hrv
classifi
three
speci
b
c
within
genu
enteroviru
famili
picornavirida
hrv
mainli
caus
upper
respiratori
tract
infect
howev
also
caus
lower
respiratori
infect
associ
exacerb
chronic
pulmonari
diseas
asthma
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
viral
persist
describ
sever
enteroviru
speci
link
clinic
entiti
eg
persist
infect
polioviru
associ
postpolio
syndrom
persist
infect
coxsackieviru
associ
chronic
myocard
dilat
cardiomyopathi
possibl
link
persist
enteroviru
infect
type
diabet
also
strongli
suspect
sever
studi
detect
enterovir
rna
andor
viral
protein
peripher
blood
andor
pancreat
tissu
patient
type
diabet
hrv
infect
usual
present
acut
infect
viral
shed
day
shown
experiment
hrv
infect
recent
studi
follow
healthi
infant
first
year
life
found
hrv
rna
rare
persist
beyond
day
hrv
infect
persist
hrv
infect
occasion
describ
immunosuppress
patient
name
transplant
recipi
patient
hypogammaglobulinemia
date
unclear
widespread
phenomenon
hrv
persist
fact
previou
studi
found
evid
hrv
persist
asthmat
children
object
present
studi
identifi
persist
hrventeroviru
infect
investig
virolog
clinic
characterist
address
object
patient
least
two
specimen
posit
hrventeroviru
taken
day
longer
apart
identifi
retrospect
hrventerovirus
type
order
determin
whether
infect
hrventeroviru
type
persist
infect
reinfect
differ
type
januari
march
respiratori
specimen
patient
sent
laboratori
virolog
lill
univers
hospit
center
test
multiplex
revers
transcriptionpolymeras
chain
reaction
rt
pcr
respiratori
virus
number
patient
specimen
test
shown
tabl
diagnost
respiratori
virus
prescrib
physician
charg
patient
hospit
centr
systemat
virolog
surveil
perform
respiratori
virus
even
sever
immunocompromis
patient
stem
cell
transplant
recipi
therefor
patient
least
one
respiratori
symptom
fever
demograph
data
age
sex
data
underli
diseas
immunosuppress
retrospect
obtain
hospit
record
studi
carri
accord
declar
helsinki
approv
institut
review
board
de
protect
de
personn
nord
ouest
iv
waiver
inform
consent
therefor
inform
consent
obtain
retrospect
nonintervent
studi
addit
procedur
specimen
initi
sent
physician
diagnost
test
respiratori
virus
patient
includ
persist
infect
group
detect
hrventeroviru
type
defin
nucleic
acid
sequenc
ident
two
respiratori
specimen
taken
interv
day
hrv
day
fig
time
interv
day
chosen
normal
durat
viral
shed
experiment
hrv
infect
day
case
hrventeroviru
type
detect
first
last
specimen
patient
specimen
obtain
systemat
submit
type
howev
hrventeroviru
type
differ
first
last
specimen
patient
specimen
obtain
submit
type
patient
includ
persist
infect
group
includ
reinfect
group
even
hesh
episod
reinfect
anoth
hrv
type
patient
includ
reinfect
group
detect
differ
hrventeroviru
type
two
respiratori
specimen
taken
interv
day
hrv
day
fig
clear
infect
patient
includ
clear
infect
group
respiratori
specimen
detect
hrventeroviru
follow
specimen
without
hrventeroviru
detect
taken
day
posit
specimen
hrv
day
apart
fig
infecti
episod
infect
hrventeroviru
type
urt
upper
respiratori
tract
specimen
urt
nasopharyng
swab
aspir
lrt
lower
respiratori
tract
specimen
lrt
bronchoalveolar
lavag
fluid
bronchial
tracheal
aspir
respiratori
specimen
store
rna
extract
rna
extract
use
magtrat
system
use
magdea
viral
dnarna
gc
kit
precis
system
scienc
co
ltd
japan
accord
manufactur
instruct
rna
extract
submit
commerci
avail
multiplex
rtpcr
screen
panel
respiratori
viral
pathogen
includ
influenza
viru
b
respiratori
syncyti
viru
b
human
adenoviru
human
metapneumoviru
coronaviru
parainfluenza
viru
hrv
ab
seeplex
ace
detect
seegen
seoul
korea
januari
septemb
specimen
commerci
avail
multiplex
rtpcr
screen
panel
respiratori
viral
pathogen
includ
influenza
viru
b
respiratori
syncyti
viru
b
human
adenoviru
hadv
human
metapneumoviru
coronavirus
parainfluenza
viru
hrv
abc
enteroviru
bocaviru
anyplex
ii
detect
seegen
seoul
korea
octob
march
specimen
accord
manufactur
detect
limit
sensit
assay
copiesreact
correspond
copiesml
respiratori
specimen
detect
limit
assay
indic
manufactur
aliquot
respiratori
specimen
store
use
type
hrventeroviru
posit
specimen
type
amplif
sequenc
viral
protein
vp
region
use
primer
describ
wisdom
et
al
briefli
revers
transcript
amplif
perform
use
superscript
iii
onestep
rtpcr
system
platinum
taq
dna
polymeras
invitrogen
thermofish
scientif
mix
contain
reaction
mix
pmol
primer
os
oa
rtplatinum
taq
mix
extrac
nucleic
acid
rt
pcr
perform
follow
thermal
profil
minut
min
min
follow
cycl
second
min
follow
cycl
min
final
extens
min
nest
pcr
perform
use
amplitaq
dna
polymeras
buffer
appli
biosystem
thermofish
scientif
rt
pcr
product
ad
mix
contain
buffer
dntp
amplitaq
dna
polymeras
mm
pmol
primer
ia
reaction
perform
follow
thermal
profil
min
follow
cycl
min
follow
cycl
min
final
extens
min
pcr
product
sequenc
directli
verif
amplif
yield
pcr
product
correct
size
agaros
gel
sequenc
assembl
align
hrventeroviru
genom
use
seqscap
softwar
appli
biosystem
consensu
sequenc
submit
basic
local
align
search
tool
blast
http
blastncbinlmnihgov
use
blastn
algorithm
order
identifi
nearest
hrventeroviru
type
addit
sequenc
align
phylogenet
tree
construct
use
megasoftwar
mega
use
neighbour
join
maximum
likelihood
method
includ
refer
sequenc
hrventeroviru
type
confirm
nearest
hrventeroviru
type
phylogenet
tree
limit
specimen
studi
one
refer
sequenc
hrva
b
c
well
coxsackieviru
construct
fig
use
megasoftwar
mega
neighbour
join
method
maximum
composit
likelihood
model
pairwis
delet
bootstrap
perform
replic
neighbour
join
tree
partial
sequenc
construct
use
mega
number
indic
patient
letter
specimen
first
chronolog
coxsackieviru
use
outgroup
percentag
bootstrap
support
correspond
clade
shown
node
higher
hrva
b
c
coxsackieviru
refer
sequenc
includ
scale
bar
indic
nucleotid
substitut
per
site
persist
infect
indic
black
squar
genbank
access
number
sequenc
obtain
studi
indic
text
patient
first
two
specimen
unavail
type
therefor
specimen
g
report
statist
analysi
perform
use
ibm
spss
statist
ibm
unit
state
onlin
statist
tool
http
insiliconettoolsstatisticsfisherexacttest
pvalu
consid
signific
continu
nonparametr
variabl
compar
use
kruskalw
test
posthoc
test
appropri
categor
variabl
compar
use
pearson
chisquar
fisher
exact
test
appropri
differ
three
group
signific
pairwis
comparison
perform
bonferroni
correct
appli
adjust
multipl
comparison
logist
regress
stepwis
backward
variabl
select
perform
compar
persist
group
combin
group
includ
patient
clear
infect
reinfect
follow
variabl
pvalu
univari
analysi
includ
logist
regress
analysi
hematolog
disord
immunosuppress
age
signific
level
chosen
inclus
variabl
logist
regress
model
remain
includ
model
patient
two
specimen
test
fig
patient
specimen
test
posit
hrventeroviru
hrv
patient
specimen
test
posit
hrventeroviru
follow
specimen
test
neg
hrventeroviru
hrv
patient
specimen
test
neg
hrventeroviru
follow
specimen
test
posit
hrventeroviru
hrv
patient
specimen
test
neg
hrventeroviru
hrv
fig
detail
distribut
patient
group
regard
total
number
specimen
test
per
patient
shown
tabl
patient
specimen
test
posit
hrventeroviru
hrv
patient
repeat
detect
hrventeroviru
respiratori
specimen
taken
least
day
apart
specimen
patient
avail
type
type
success
specimen
patient
hrva
hrvb
hrvc
coxsackieviru
one
patient
second
specimen
untyp
exclud
analysi
phylogenet
analysi
region
hrventeroviru
posit
specimen
patient
shown
fig
patient
detect
hrventeroviru
type
least
two
respiratori
specimen
taken
least
day
apart
thu
fullfil
criteria
persist
hrventeroviru
infect
fig
underli
condit
patient
persist
infect
acut
myeloid
leukaemia
n
acut
lymphoblast
leukaemia
n
chronic
lymphocyt
leukaemia
n
multipl
myeloma
n
hemophagocyt
syndrom
n
bone
marrow
aplasia
n
myelofibrosi
n
myelodysplast
syndrom
n
hodgkin
diseas
n
polyarter
nodosa
n
cystic
fibrosi
n
patient
persist
infect
undergon
allogen
stem
cell
transplant
among
patient
persist
infect
minimum
median
durat
hrventeroviru
shed
ie
time
interv
first
last
specimen
hrv
type
day
rang
day
patient
reinfect
differ
hrventeroviru
type
fig
patient
hrventeroviru
posit
specimen
follow
hrventeroviru
neg
specimen
interv
day
patient
includ
clear
infect
group
fig
clinic
characterist
three
group
shown
tabl
age
significantli
differ
three
group
p
tabl
immunosuppress
hematolog
disord
underli
condit
associ
persist
infect
p
p
respect
tabl
variabl
age
hematolog
disord
associ
persist
infect
logist
regress
analaysi
detect
respiratori
virus
rel
frequent
three
group
tabl
nearest
hrventeroviru
type
durat
viru
shed
respiratori
site
hrventeroviru
detect
respiratori
virus
detect
shown
tabl
patient
persist
infect
hrva
detect
patient
persist
infect
first
episod
infect
persist
infect
compar
reinfect
persist
infect
group
respect
statist
signific
associ
hrventeroviru
speci
persist
p
tabl
present
studi
systemat
search
hrventeroviru
persist
identifi
patient
persist
hrventeroviru
infect
knowledg
largest
case
seri
persist
hrventeroviru
infect
far
publish
patient
studi
hospit
immunosuppress
frequent
one
patient
persist
infect
immunosuppress
immunosuppress
associ
hrventeroviru
persist
p
tabl
patient
persist
infect
immunosuppress
suffer
cystic
fibrosi
knowledg
one
report
hrv
persist
cystic
fibrosi
patient
name
hrva
infect
yearoldpati
contrast
patient
infect
hematolog
disord
underli
condit
patient
hrventeroviru
persist
statist
associ
persist
p
tabl
interestingli
recent
studi
found
hrv
persist
paediatr
hematopoiet
stem
cell
transplant
recipi
studi
patient
persist
infect
stem
cell
transplant
recipi
child
adult
popul
highli
immunosuppress
patient
seem
predispos
hrventeroviru
persist
minimum
median
durat
hrventeroviru
persist
patient
day
rang
day
knowledg
longer
durat
persist
far
describ
twice
respiratori
virus
frequent
detect
respiratori
specimen
patient
persist
hrventeroviru
infect
patient
reinfect
patient
clear
infect
tabl
tabl
confirm
find
loeffelholz
et
al
although
studi
commonli
concomitantli
detect
virus
coronavirus
human
adenovirus
tabl
interestingli
persist
infect
caus
hrva
howev
statist
signific
associ
speci
hrv
persist
found
may
due
rel
small
number
patient
persist
infect
retrospect
studi
follow
limit
specimen
sent
diagnost
respiratori
virus
upon
prescript
physician
charg
patient
although
systemat
surveil
respiratori
virus
perform
centr
possibl
bia
far
physician
probabl
prescrib
readili
diagnost
respiratori
virus
patient
hesh
judg
increas
risk
may
led
overrepresent
immunosuppress
patient
studi
popul
howev
fact
immunosuppress
patient
probabl
specimen
sent
diagnost
respiratori
virus
mean
necessarili
persist
infect
support
fact
specimen
number
significantli
differ
reinfect
persist
group
tabl
howev
signific
differ
specimen
number
per
patient
clear
infect
group
versu
two
group
tabl
second
respiratori
specimen
obtain
variou
time
interv
follow
first
hrventeroviru
posit
specimen
persist
assum
patient
harbour
hrventeroviru
type
consecut
specimen
even
taken
long
time
interv
reinfect
type
seem
extrem
unlik
due
host
immun
due
high
number
circul
type
hrv
patient
find
evid
persist
ie
differ
hrv
type
second
specimen
data
durat
infect
differ
hrv
type
point
address
futur
studi
well
clinic
relev
hrv
persist
import
like
persist
enterovirus
hrv
persist
might
associ
chronic
diseas
exampl
diabet
type
dilat
cardiomyopathi
fact
second
respiratori
specimen
obtain
variou
time
interv
follow
first
hrventeroviru
posit
specimen
also
impact
clear
infect
group
patient
neg
followup
specimen
taken
time
interv
day
first
specimen
thu
permit
classifi
clear
infect
patient
neg
followup
specimen
taken
day
longer
first
specimen
thu
persist
infect
accord
definit
could
exclud
therefor
patient
includ
clear
infect
group
two
differ
assay
detect
respiratori
virus
use
studi
period
seeplex
ace
detect
assay
includ
detect
hrvc
therefor
hrvc
infect
probabl
diagnos
specimen
test
assay
specimen
repres
specimen
studi
conclus
retrospect
studi
identifi
patient
hrventeroviru
persist
vivo
persist
occur
mainli
immunosuppress
patient
